Table 1.
Modulation of evoked IPSCs (eIPSCs) and mIPSCs
| Agent | Amplitude (pA) | Latency (msec) | Frequency (Hz) | n | |||
|---|---|---|---|---|---|---|---|
| Control | Agent | Control | Agent | Control | Agent | ||
| eIPSCs | |||||||
| D1 agonists | 89.2 ± 12.3 | 193.9 ± 35.71-a | 3.2 ± 0.2 | 2.6 ± 0.11-a | 13 | ||
| Fors | 81.2 ± 32.1 | 273.6 ± 91.5 | 3.1 ± 0.2 | 2.6 ± 0.11-a | 4 | ||
| SCH | 113.5 ± 30.8 | 41.9 ± 10.9 | 3.2 ± 0.1* | 3.3 ± 0.2*1-a | 4 (3*) | ||
| mIPSCs | |||||||
| D1 agonists | 46.2 ± 10.6 | 45.7 ± 8.7 | 2.0 ± 2.0 | 6.0 ± 6.31-a | 9 | ||
| Fors | 39.7 ± 12.2 | 40.2 ± 8.6 | 1.4 ± 0.5 | 4.4 ± 1.41-a | 4 | ||
| SCH | 41.1 ± 11.4 | 45.9 ± 11.6 | 1.0 ± 0.8 | 1.0 ± 0.7 | 5 | ||
Data are given as mean ± SEM. mIPSCs were recorded in the presence of TTX (0.3 μm) and Cd2+ (20–100 μm). D1 agonists, SKF38393 (3–20 μm) and DA (10 μm + D2antagonist sulpiride 1 μm). Fors, Forskolin (5–20 μm). SCH, D1 antagonist SCH23390 (0.1–1 μm).
F1-a
p < 0.05, two-tailed Student’s test.
* h = 3 for latency measurement.